Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Mohty, 2019, CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives, Leukemia, 33, 2767, 10.1038/s41375-019-0615-5 Jain, 2019, Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy, Biol Blood Marrow Transplant, 25, 2305, 10.1016/j.bbmt.2019.08.015 Byrne, 2019, Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy, Biol Blood Marrow Transplant, 25, e344, 10.1016/j.bbmt.2019.06.036 Perica, 2018, Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center, Biol Blood Marrow Transplant, 24, 1135, 10.1016/j.bbmt.2018.02.018 June, 2018, Chimeric antigen receptor therapy, N Engl J Med, 379, 64, 10.1056/NEJMra1706169 Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies[e-pub ahead of print]. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2019.11.027, accessed December 2019. Moyo, 2020, Late psychiatric and neurocognitive effects of chimeric antigen receptor T cell therapy warrant further investigation, Biol Blood Marrow Transplant, 26, e3, 10.1016/j.bbmt.2019.11.013 Hossain, 2020, Late events after CD-19 CAR-T treatment, Biol Blood Marrow Transplant, 26, e1, 10.1016/j.bbmt.2019.10.020 Cordeiro, 2020, Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells, Biol Blood Marrow Transplant, 26, 26, 10.1016/j.bbmt.2019.08.003 Heslop, 2019, Harmonizing immune effector toxicity reporting, Biol Blood Marrow Transplant, 25, e121, 10.1016/j.bbmt.2019.01.001 Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant, 25, 625, 10.1016/j.bbmt.2018.12.758 Kansagra, 2019, Bone Marrow Transplant, 54, 1868, 10.1038/s41409-019-0451-2 Jain, 2018, No free rides: management of toxicities of novel immunotherapies in ALL, including financial, Blood Adv, 2, 3393, 10.1182/bloodadvances.2018020198 Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698 Frey, 2019, Cytokine release syndrome with chimeric antigen receptor T cell therapy, Biol Blood Marrow Transplant, 25, e123, 10.1016/j.bbmt.2018.12.756 Giavridis, 2018, CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade, Nat Med, 24, 731, 10.1038/s41591-018-0041-7 Norelli, 2018, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells, Nat Med, 24, 739, 10.1038/s41591-018-0036-4 Sterner, 2019, GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts, Blood, 133, 697, 10.1182/blood-2018-10-881722 Chakraborty, 2019, Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities, Biol Blood Marrow Transplant, 25, e155, 10.1016/j.bbmt.2018.11.025 Rule, 2010, The CKD-EPI equation for estimating GFR from serum creatinine: real improvement or more of the same?, Clin J Am Soc Nephrol, 5, 951, 10.2215/CJN.03110410 KDIGO: Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. March 2012. Available at: https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. Accessed August 2019. Mahmoudjafari, 2019, American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States, Biol Blood Marrow Transplant, 25, 26, 10.1016/j.bbmt.2018.09.024 Jain, 2019, Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma, Leukemia, 33, 2540, 10.1038/s41375-019-0476-y Glezerman, 2017, Long-term renal survival in patients undergoing T cell-depleted versus conventional hematopoietic stem cell transplants, Bone Marrow Transplant, 52, 733, 10.1038/bmt.2016.343 Hingorani, 2016, Renal complications of hematopoietic-cell transplantation, N Engl J Med, 374, 2256, 10.1056/NEJMra1404711 Ando, 2010, A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT, Bone Marrow Transplant, 45, 1427, 10.1038/bmt.2009.377 Hingorani, 2015, Estimating GFR in adult patients with hematopoietic cell transplant: comparison of estimating equations with an iohexol reference standard, Clin J Am Soc Nephrol, 10, 601, 10.2215/CJN.06470614 Schrier, 2004, Acute renal failure and sepsis, N Engl J Med, 351, 159, 10.1056/NEJMra032401 Yañez, 2019, CAR T cell toxicity: current management and future directions, Hemasphere, 3, e186, 10.1097/HS9.0000000000000186 Jhaveri, 2018, Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know, Clin J Am Soc Nephrol, 13, 796, 10.2215/CJN.12871117 Burstein, 2018, Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience, Biol Blood Marrow Transplant, 24, 1590, 10.1016/j.bbmt.2018.05.014 Linette, 2013, Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma, Blood, 122, 863, 10.1182/blood-2013-03-490565 Pennisi, 2020, Comparing CAR T-cells toxicities grading systems: application of ASTCT grading system and implications for management, Blood Adv, 4, 676, 10.1182/bloodadvances.2019000952 Mohammed, 2013, Contrast-induced nephropathy, Heart Views, 14, 106, 10.4103/1995-705X.125926 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Dixon, 2020, Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells, Clin Nephrol, 93, 42, 10.5414/CN109872